Interseting new future product?

[Guest guest]

" Our second drug candidate, Androxal(TM: 109.80, +1.48, +1.36%), is

designed to restore normal pituitary response resulting in

normalization of testosterone levels. According to the Urology

Channel, recent estimates show that approximately 13 million men in

the United States experience testosterone deficiency. Repros recently

completed an Androxal non-pivotal six-month U.S. Phase 3 clinical

trial and has enrolled patients from this trial into a one-year

open-label safety study. We intend to develop Androxal for the

treatment of fertility preservation and improvement in patients that

want to preserve their fertility while being treated for low

testosterone associated with secondary hypogonadism. In addition, we

also intend to develop Androxal for the treatment of men with

idiopathic adult onset hypogonadotropic hypogonadism associated with

glycemic and lipid dysregulation.

For more information, please visit the Company's website at

http://www.reprosrx.com. "

http://www.foxbusiness.com/markets/industries/health-care/article/repros-announc\

es-2008-annual-shareholders-meeting_460649_10.html